Derek Maetzold Sells 830 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 830 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $40.35, for a total value of $33,490.50. Following the transaction, the insider directly owned 33,530 shares in the company, valued at $1,352,935.50. This trade represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Castle Biosciences Stock Performance

CSTL stock opened at $39.31 on Wednesday. The company has a market capitalization of $1.15 billion, a P/E ratio of -87.36 and a beta of 1.14. The company has a 50-day simple moving average of $35.23 and a 200 day simple moving average of $25.78. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $42.17. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The firm had revenue of $80.55 million for the quarter, compared to analysts’ expectations of $71.06 million. Sell-side analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on CSTL shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday. BTIG Research upped their price objective on Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a report on Friday, December 12th. Zacks Research raised Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Robert W. Baird boosted their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. Finally, Canaccord Genuity Group upped their price target on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Castle Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. increased its stake in Castle Biosciences by 17.1% in the 1st quarter. Invesco Ltd. now owns 32,251 shares of the company’s stock worth $646,000 after purchasing an additional 4,717 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Castle Biosciences by 158.9% in the first quarter. Russell Investments Group Ltd. now owns 18,669 shares of the company’s stock worth $373,000 after buying an additional 11,457 shares during the period. American Century Companies Inc. increased its position in shares of Castle Biosciences by 7.1% in the first quarter. American Century Companies Inc. now owns 74,067 shares of the company’s stock worth $1,483,000 after acquiring an additional 4,892 shares in the last quarter. Trexquant Investment LP raised its holdings in shares of Castle Biosciences by 22.3% during the first quarter. Trexquant Investment LP now owns 248,991 shares of the company’s stock valued at $4,985,000 after acquiring an additional 45,420 shares during the period. Finally, Magnetar Financial LLC acquired a new stake in shares of Castle Biosciences during the first quarter valued at approximately $225,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.